Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00369824 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,330
- Enrollment target
NCT00369824 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,330 participants.
The verdict
NCT00369824, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,330 participants
- Enrollment target
Study Summary
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a rational strategy for prevention of cervical cancer, and so HPV vaccination could complement the existing pre-adolescent/adolescents platform. Therefore, this Phase 3b study is designed to evaluate the safety and immunogenicity of co-administering Boostrix and/or Menactra with GSK Biologicals' HPV vaccine (580299) as compared to the administration of any of the vaccines alone. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Interventions
- BIOLOGICAL Different formulations of GSK Biologicals' HPV vaccine (580299)
- BIOLOGICAL Menactra TM
- BIOLOGICAL Boostrix TM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,330 participants |
| Start Date | 2006-09-26 |
| Est. Completion | 2008-02-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00369824
The ClinicalTrials.gov registry entry for NCT00369824 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Different formulations of GSK Biologicals' HPV vaccine (580299) is the first listed.
NCT00369824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00369824 about?
NCT00369824 is a clinical study titled "Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects". Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a rational strategy for prevention of cervical cancer, and so HPV vaccin...
What is the current status of trial NCT00369824?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,330 participants. The study started on 2006-09-26. Estimated completion is 2008-02-13.
What interventions are being tested in trial NCT00369824?
The interventions under investigation include: Different formulations of GSK Biologicals' HPV vaccine (580299) (BIOLOGICAL), Menactra TM (BIOLOGICAL), Boostrix TM (BIOLOGICAL).
Who is sponsoring clinical trial NCT00369824?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.